Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types

Summary

This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in 6 cohorts of patients with specific rare cancers who have unresectable locally advanced or metastatic disease, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available.

Timeline

Start

2017-06-16

Primary completion

2022-12-22

Completion

2023-11-11

Drugs

Indications